Sir Greg Winter, a founder of both Cambridge Antibody Technology and Domantis, has put his scientific and entrepreneurial skills to work again as the scientific co-founder of new company in the UK that is developing mini-antibodies.
The pharmaceutical industry must move quickly to change its business model in order to be able to deliver new products in the future, Jean-Claude Muller of sanofi-aventis told a meeting of industry executives.
An international team of scientists has reported finding four new single-letter variations in the sequence of the human genome which confers an increased risk of prostate cancer. The findings were published online in Nature Genetics.
A new compound has been identified that could play a role in treating cancers that are dependent on a complex network of proteins known as the Wnt signalling pathway. The findings were reported in the science journal, Nature.
Scientists from the UK and France have identified three genes that appear to increase a person’s chances of developing Alzheimer’s disease, the most common cause of dementia.
Researchers from industry and two non-profit organisations have reported the discovery of two new broadly neutralising antibodies against the human immunodeficiency virus (HIV), thus advancing the goal of developing an AIDS vaccine.
Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, has been reported to show an improvement in lung function in patients with chronic obstructive pulmonary disease in four Phase 3 trials published in The Lancet. The drug is produced by Nycomed.
Crucell NV of the Netherlands said the US government has agreed to fund further clinical studies of its adenovirus-based vaccine technology against the malaria parasite, Plasmodium falciparum.
A new web-based portal designed to help scientists and clinicians locate the latest cancer research has been launched by the UK National Cancer Research Institute (NCRI). The project is being funded by the UK government, charities and industry.
Sanofi-aventis has become the latest multinational pharmaceutical company to decentralise its research and development business in order to generate more ideas for new drugs from contact with scientists and entrepreneurs outside the company.